In the Spotlight - Although the mid-December hookup of Amgen Inc. and Immunex Corp. is not expected to touch off a round of reactionary dealmaking in the biotech industry, industry experts think that as companies look to expand their product portfolios and add infrastructure to manage product marketing and distribution, m&a will serve as an attractive avenue of growth for them.
Year of publication:
Mergers & acquisitions. - New York, NY : Investment Dealers' Digest, ISSN 0026-0010, ZDB-ID 8628555. - Vol. 37.2002, 3, p. 23-24